JPH08509474A - 経口薬剤移送組成物およびその方法 - Google Patents
経口薬剤移送組成物およびその方法Info
- Publication number
- JPH08509474A JPH08509474A JP6523595A JP52359594A JPH08509474A JP H08509474 A JPH08509474 A JP H08509474A JP 6523595 A JP6523595 A JP 6523595A JP 52359594 A JP52359594 A JP 52359594A JP H08509474 A JPH08509474 A JP H08509474A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- amino acid
- composition
- alkyl
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 123
- 238000000034 method Methods 0.000 title claims abstract description 35
- 229940126701 oral medication Drugs 0.000 title abstract description 5
- 238000012546 transfer Methods 0.000 title description 10
- 150000001413 amino acids Chemical class 0.000 claims abstract description 158
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 67
- 239000013543 active substance Substances 0.000 claims abstract description 53
- 239000004005 microsphere Substances 0.000 claims abstract description 49
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 26
- 241001465754 Metazoa Species 0.000 claims abstract description 14
- 229940024606 amino acid Drugs 0.000 claims description 168
- 235000001014 amino acid Nutrition 0.000 claims description 168
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 78
- -1 monoclonal antibody Proteins 0.000 claims description 60
- 102000055006 Calcitonin Human genes 0.000 claims description 57
- 108060001064 Calcitonin Proteins 0.000 claims description 57
- 229960004015 calcitonin Drugs 0.000 claims description 57
- 150000001299 aldehydes Chemical class 0.000 claims description 46
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 35
- 125000001624 naphthyl group Chemical group 0.000 claims description 28
- 239000002253 acid Substances 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 22
- 239000004472 Lysine Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 150000002576 ketones Chemical class 0.000 claims description 17
- 238000009472 formulation Methods 0.000 claims description 14
- 229960003136 leucine Drugs 0.000 claims description 14
- 229910001868 water Inorganic materials 0.000 claims description 14
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 13
- 125000003342 alkenyl group Chemical group 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- 229960005190 phenylalanine Drugs 0.000 claims description 13
- QUPKQMCKNRWZBH-UHFFFAOYSA-N 4-(benzenesulfonamido)-4-phenylbutanoic acid Chemical compound C=1C=CC=CC=1C(CCC(=O)O)NS(=O)(=O)C1=CC=CC=C1 QUPKQMCKNRWZBH-UHFFFAOYSA-N 0.000 claims description 12
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 12
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 12
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 12
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 12
- 235000008729 phenylalanine Nutrition 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 11
- 102000004877 Insulin Human genes 0.000 claims description 11
- 108090001061 Insulin Proteins 0.000 claims description 11
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 11
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 11
- 229940125396 insulin Drugs 0.000 claims description 11
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims description 10
- 239000004475 Arginine Substances 0.000 claims description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 10
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 10
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 10
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 10
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 10
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 10
- XJLATMLVMSFZBN-VYDXJSESSA-N actinonin Chemical compound CCCCC[C@H](CC(=O)NO)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1CO XJLATMLVMSFZBN-VYDXJSESSA-N 0.000 claims description 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 10
- 235000009697 arginine Nutrition 0.000 claims description 10
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 10
- 235000018417 cysteine Nutrition 0.000 claims description 10
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 10
- 229960002433 cysteine Drugs 0.000 claims description 10
- 229930182817 methionine Natural products 0.000 claims description 10
- 229960003104 ornithine Drugs 0.000 claims description 10
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 10
- 229960004295 valine Drugs 0.000 claims description 10
- 239000003981 vehicle Substances 0.000 claims description 10
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 9
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 9
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 claims description 9
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 9
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 9
- 229960002897 heparin Drugs 0.000 claims description 9
- 229920000669 heparin Polymers 0.000 claims description 9
- 229960002591 hydroxyproline Drugs 0.000 claims description 9
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 9
- 239000004474 valine Substances 0.000 claims description 9
- 102000000588 Interleukin-2 Human genes 0.000 claims description 8
- 108010002350 Interleukin-2 Proteins 0.000 claims description 8
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims description 8
- XJLATMLVMSFZBN-UHFFFAOYSA-N actinonine Natural products CCCCCC(CC(=O)NO)C(=O)NC(C(C)C)C(=O)N1CCCC1CO XJLATMLVMSFZBN-UHFFFAOYSA-N 0.000 claims description 8
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 claims description 8
- 235000008206 alpha-amino acids Nutrition 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 claims description 8
- 229960000958 deferoxamine Drugs 0.000 claims description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000003607 modifier Substances 0.000 claims description 7
- REOCNKZXONOGGX-ABLWVSNPSA-N (2s)-2-[(2-carboxy-3-phenylpropanoyl)amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)C(C(O)=O)CC1=CC=CC=C1 REOCNKZXONOGGX-ABLWVSNPSA-N 0.000 claims description 6
- GTOFKXZQQDSVFH-UHFFFAOYSA-N 2-benzylsuccinic acid Chemical compound OC(=O)CC(C(O)=O)CC1=CC=CC=C1 GTOFKXZQQDSVFH-UHFFFAOYSA-N 0.000 claims description 6
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 6
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 6
- 108010050904 Interferons Proteins 0.000 claims description 6
- 102000014150 Interferons Human genes 0.000 claims description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108010006025 bovine growth hormone Proteins 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 229940079322 interferon Drugs 0.000 claims description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 5
- JZJXIRJMLZJQIF-LMECJBHSSA-N (2s)-2-amino-4-methylpentanoic acid;(2s)-2-(carboxymethylamino)-3-phenylpropanoic acid Chemical compound CC(C)C[C@H](N)C(O)=O.OC(=O)CN[C@H](C(O)=O)CC1=CC=CC=C1 JZJXIRJMLZJQIF-LMECJBHSSA-N 0.000 claims description 5
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 claims description 5
- XDOLZJYETYVRKV-UHFFFAOYSA-N 7-Aminoheptanoic acid Chemical compound NCCCCCCC(O)=O XDOLZJYETYVRKV-UHFFFAOYSA-N 0.000 claims description 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 5
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims description 5
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 5
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 5
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 claims description 5
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 5
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 5
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 claims description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 5
- 102400000050 Oxytocin Human genes 0.000 claims description 5
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims description 5
- 101800000989 Oxytocin Proteins 0.000 claims description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 5
- 239000004473 Threonine Substances 0.000 claims description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- 150000001408 amides Chemical class 0.000 claims description 5
- 235000009582 asparagine Nutrition 0.000 claims description 5
- 229960001230 asparagine Drugs 0.000 claims description 5
- 229940000635 beta-alanine Drugs 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 229960003067 cystine Drugs 0.000 claims description 5
- 239000004220 glutamic acid Substances 0.000 claims description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 5
- 229960000310 isoleucine Drugs 0.000 claims description 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 5
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims description 5
- 229960001723 oxytocin Drugs 0.000 claims description 5
- 150000003457 sulfones Chemical group 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000004434 sulfur atom Chemical group 0.000 claims description 5
- LSKOJLKNJUNBAC-UHFFFAOYSA-N 2-benzamidoacetyl chloride Chemical compound ClC(=O)CNC(=O)C1=CC=CC=C1 LSKOJLKNJUNBAC-UHFFFAOYSA-N 0.000 claims description 4
- RBHLFWNKEWLHBP-UHFFFAOYSA-N 4-(4-aminophenyl)butanoic acid Chemical compound NC1=CC=C(CCCC(O)=O)C=C1 RBHLFWNKEWLHBP-UHFFFAOYSA-N 0.000 claims description 4
- 108010016626 Dipeptides Proteins 0.000 claims description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 4
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims description 4
- HSMNQINEKMPTIC-UHFFFAOYSA-N N-(4-aminobenzoyl)glycine Chemical compound NC1=CC=C(C(=O)NCC(O)=O)C=C1 HSMNQINEKMPTIC-UHFFFAOYSA-N 0.000 claims description 4
- 108010059993 Vancomycin Proteins 0.000 claims description 4
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims description 4
- 102000002852 Vasopressins Human genes 0.000 claims description 4
- 108010004977 Vasopressins Proteins 0.000 claims description 4
- 229960004050 aminobenzoic acid Drugs 0.000 claims description 4
- 229960004567 aminohippuric acid Drugs 0.000 claims description 4
- 239000011260 aqueous acid Substances 0.000 claims description 4
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 235000013772 propylene glycol Nutrition 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 4
- 229960003165 vancomycin Drugs 0.000 claims description 4
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 4
- 229960003726 vasopressin Drugs 0.000 claims description 4
- 102000003951 Erythropoietin Human genes 0.000 claims description 3
- 108090000394 Erythropoietin Proteins 0.000 claims description 3
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 3
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 3
- 239000000854 Human Growth Hormone Substances 0.000 claims description 3
- 102000005157 Somatostatin Human genes 0.000 claims description 3
- 108010056088 Somatostatin Proteins 0.000 claims description 3
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 239000003086 colorant Substances 0.000 claims description 3
- 229960000265 cromoglicic acid Drugs 0.000 claims description 3
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 229940105423 erythropoietin Drugs 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims description 3
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 3
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 3
- 229960000553 somatostatin Drugs 0.000 claims description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 2
- KHMNCHDUSFCTGK-UHFFFAOYSA-N 2-aminophenylacetic acid Chemical compound NC1=CC=CC=C1CC(O)=O KHMNCHDUSFCTGK-UHFFFAOYSA-N 0.000 claims description 2
- 101800000414 Corticotropin Proteins 0.000 claims description 2
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 claims description 2
- DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 102100027467 Pro-opiomelanocortin Human genes 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- 230000010933 acylation Effects 0.000 claims description 2
- 238000005917 acylation reaction Methods 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 2
- 229960000258 corticotropin Drugs 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 239000002917 insecticide Substances 0.000 claims description 2
- 239000002304 perfume Substances 0.000 claims description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 239000003488 releasing hormone Substances 0.000 claims description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 8
- 230000001746 atrial effect Effects 0.000 claims 5
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 4
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims 4
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 4
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 4
- 229960002684 aminocaproic acid Drugs 0.000 claims 4
- UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 claims 4
- 235000013477 citrulline Nutrition 0.000 claims 4
- 229960002173 citrulline Drugs 0.000 claims 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 4
- 229960002743 glutamine Drugs 0.000 claims 4
- 229960002449 glycine Drugs 0.000 claims 4
- 229960003646 lysine Drugs 0.000 claims 4
- 229960004452 methionine Drugs 0.000 claims 4
- 229940124530 sulfonamide Drugs 0.000 claims 4
- 150000003456 sulfonamides Chemical class 0.000 claims 4
- GTVVZTAFGPQSPC-UHFFFAOYSA-N 4-nitrophenylalanine Chemical compound OC(=O)C(N)CC1=CC=C([N+]([O-])=O)C=C1 GTVVZTAFGPQSPC-UHFFFAOYSA-N 0.000 claims 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims 2
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims 2
- 239000004081 narcotic agent Substances 0.000 claims 2
- 239000008196 pharmacological composition Substances 0.000 claims 2
- CLTMYNWFSDZKKI-UHFFFAOYSA-N 2-(aminomethyl)benzoic acid Chemical compound NCC1=CC=CC=C1C(O)=O CLTMYNWFSDZKKI-UHFFFAOYSA-N 0.000 claims 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims 1
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 claims 1
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- 101100119979 Mus musculus Ferd3l gene Proteins 0.000 claims 1
- 101710142969 Somatoliberin Proteins 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 claims 1
- 229910000071 diazene Inorganic materials 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims 1
- 108010000761 leucylarginine Proteins 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 150000003460 sulfonic acids Chemical class 0.000 claims 1
- 150000003862 amino acid derivatives Chemical class 0.000 abstract description 16
- 238000002360 preparation method Methods 0.000 abstract description 16
- 238000012377 drug delivery Methods 0.000 abstract description 5
- 239000003124 biologic agent Substances 0.000 abstract description 3
- 229940093740 amino acid and derivative Drugs 0.000 abstract 1
- 230000000975 bioactive effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 61
- 241000700159 Rattus Species 0.000 description 57
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 48
- 238000003305 oral gavage Methods 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 21
- 108010068072 salmon calcitonin Proteins 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- 239000003814 drug Substances 0.000 description 19
- 229940079593 drug Drugs 0.000 description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 14
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- 239000002244 precipitate Substances 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000000654 additive Substances 0.000 description 12
- 238000003756 stirring Methods 0.000 description 11
- 108010051696 Growth Hormone Proteins 0.000 description 10
- 102000018997 Growth Hormone Human genes 0.000 description 10
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 description 10
- 239000000122 growth hormone Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- 102100040018 Interferon alpha-2 Human genes 0.000 description 8
- 108010079944 Interferon-alpha2b Proteins 0.000 description 8
- CBQJSKKFNMDLON-JTQLQIEISA-N N-acetyl-L-phenylalanine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 CBQJSKKFNMDLON-JTQLQIEISA-N 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 230000000087 stabilizing effect Effects 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000005711 Benzoic acid Substances 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 235000010233 benzoic acid Nutrition 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229950009215 phenylbutanoic acid Drugs 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 4
- 229920000084 Gum arabic Polymers 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 235000010489 acacia gum Nutrition 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000010908 decantation Methods 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- TYZXWNYMZXLYSH-AWEZNQCLSA-N (2s)-2-(cyclohexanecarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)C1CCCCC1)C1=CC=CC=C1 TYZXWNYMZXLYSH-AWEZNQCLSA-N 0.000 description 3
- JQEHNLDJCJHUGI-UHFFFAOYSA-N 2-[4-(benzenesulfonamido)phenyl]acetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1NS(=O)(=O)C1=CC=CC=C1 JQEHNLDJCJHUGI-UHFFFAOYSA-N 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241001024304 Mino Species 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 150000004702 methyl esters Chemical group 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- CHOGMPPUSGFJEB-UHFFFAOYSA-N 4-(benzenesulfonamidomethyl)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CNS(=O)(=O)C1=CC=CC=C1 CHOGMPPUSGFJEB-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002144 chemical decomposition reaction Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 150000001805 chlorine compounds Chemical group 0.000 description 2
- 229940109248 cromoglycate Drugs 0.000 description 2
- WEPUZBYKXNKSDH-UHFFFAOYSA-N cyclopentanecarbonyl chloride Chemical compound ClC(=O)C1CCCC1 WEPUZBYKXNKSDH-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- VSDUZFOSJDMAFZ-VIFPVBQESA-N methyl L-phenylalaninate Chemical compound COC(=O)[C@@H](N)CC1=CC=CC=C1 VSDUZFOSJDMAFZ-VIFPVBQESA-N 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 108010073101 phenylalanylleucine Proteins 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000037074 physically active Effects 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 229920001308 poly(aminoacid) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 2
- 238000006277 sulfonation reaction Methods 0.000 description 2
- 108010021724 tonin Proteins 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- JNBVLGDICHLLTN-DZUOILHNSA-N (2s)-2-acetamido-n-[(2s,3s)-4-[[[(2s)-2-acetamido-3-methylbutanoyl]amino]-(cyclohexylmethyl)amino]-3-hydroxy-1-phenylbutan-2-yl]-3-methylbutanamide Chemical compound C([C@H](NC(=O)[C@@H](NC(C)=O)C(C)C)[C@@H](O)CN(CC1CCCCC1)NC(=O)[C@@H](NC(C)=O)C(C)C)C1=CC=CC=C1 JNBVLGDICHLLTN-DZUOILHNSA-N 0.000 description 1
- GTVVZTAFGPQSPC-QMMMGPOBSA-N (2s)-2-azaniumyl-3-(4-nitrophenyl)propanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=C([N+]([O-])=O)C=C1 GTVVZTAFGPQSPC-QMMMGPOBSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- 150000005207 1,3-dihydroxybenzenes Chemical class 0.000 description 1
- NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 1
- CSEWAUGPAQPMDC-UHFFFAOYSA-N 2-(4-aminophenyl)acetic acid Chemical compound NC1=CC=C(CC(O)=O)C=C1 CSEWAUGPAQPMDC-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- YAGOYAVZOJQMRT-UHFFFAOYSA-N 4-(benzenesulfonamido)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NS(=O)(=O)C1=CC=CC=C1 YAGOYAVZOJQMRT-UHFFFAOYSA-N 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- LQVXSNNAFNGRAH-QHCPKHFHSA-N BMS-754807 Chemical compound C([C@@]1(C)C(=O)NC=2C=NC(F)=CC=2)CCN1C(=NN1C=CC=C11)N=C1NC(=NN1)C=C1C1CC1 LQVXSNNAFNGRAH-QHCPKHFHSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- XEANQLOFVBFKGF-VWMHFEHESA-N CC(C)[C@H](N)C(O)=O.ClS(=O)(=O)C1=CC=CC=C1 Chemical compound CC(C)[C@H](N)C(O)=O.ClS(=O)(=O)C1=CC=CC=C1 XEANQLOFVBFKGF-VWMHFEHESA-N 0.000 description 1
- 102100038521 Calcitonin gene-related peptide 2 Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical group O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical class OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 101710126321 Pancreatic trypsin inhibitor Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000012345 acetylating agent Substances 0.000 description 1
- 229960000669 acetylleucine Drugs 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- QCTBMLYLENLHLA-UHFFFAOYSA-N aminomethylbenzoic acid Chemical compound NCC1=CC=C(C(O)=O)C=C1 QCTBMLYLENLHLA-UHFFFAOYSA-N 0.000 description 1
- 229960003375 aminomethylbenzoic acid Drugs 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- CHIHQLCVLOXUJW-UHFFFAOYSA-N benzoic anhydride Chemical compound C=1C=CC=CC=1C(=O)OC(=O)C1=CC=CC=C1 CHIHQLCVLOXUJW-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- RVOJTCZRIKWHDX-UHFFFAOYSA-N cyclohexanecarbonyl chloride Chemical compound ClC(=O)C1CCCCC1 RVOJTCZRIKWHDX-UHFFFAOYSA-N 0.000 description 1
- JOHUAELJNSBTGS-UHFFFAOYSA-N cyclohexanecarbonyl cyclohexanecarboxylate Chemical compound C1CCCCC1C(=O)OC(=O)C1CCCCC1 JOHUAELJNSBTGS-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- KZTYYGOKRVBIMI-UHFFFAOYSA-N diphenyl sulfone Chemical compound C=1C=CC=CC=1S(=O)(=O)C1=CC=CC=C1 KZTYYGOKRVBIMI-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 150000003948 formamides Chemical class 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical group 0.000 description 1
- LZXXNPOYQCLXRS-UHFFFAOYSA-N methyl 4-aminobenzoate Chemical compound COC(=O)C1=CC=C(N)C=C1 LZXXNPOYQCLXRS-UHFFFAOYSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- APVPOHHVBBYQAV-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyloctadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 APVPOHHVBBYQAV-UHFFFAOYSA-N 0.000 description 1
- ITFVSOSPSXRHDM-HNNXBMFYSA-N n-[(2s)-1-oxo-3-phenylpropan-2-yl]cyclohexanecarboxamide Chemical compound C([C@@H](C=O)NC(=O)C1CCCCC1)C1=CC=CC=C1 ITFVSOSPSXRHDM-HNNXBMFYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002993 phenylalanine derivatives Chemical class 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012485 toluene extract Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 229940108519 trasylol Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/55—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. (A)少なくとも1つの生物学的活性剤と; (B)少なくとも1つのキャリアとを含有する組成物であって、該キャリアが 、 (a)(i)アミノ酸の少なくとも1つのアシル化アルデヒド、 (ii)アミノ酸の少なくとも1つのアシル化ケトン、 (iii)ペプチドの少なくとも1つのアシル化アルデヒド、 (iv)ペプチドの少なくとも1つのアシル化ケトン、または、 (v)(a)(i)、(a)(ii)、(a)(iii)、および(a)(iv)の 種々の組み合わせ; (b)(i)カルボキシメチル−フェニルアラニン−ロイシン、 (ii)2−カルボキシ−3−フェニルプロピオニル−ロイシン、 (iii)2−ベンジルコハク酸、または、 (iv)アクチノニン、または、 (v)式: Ar−Y−(R1)n−OH (式中、Arは、置換または無置換フェニルまたはナフチルであり; Yは、−CO−または−SO2−であり; R1は、−N(R4)−R3−CO−であり; ここで、R3は、C1からC24アルキル、C1からC24アルケニル、フェニル 、ナフチル、(C1からC10アルキル)フェニル、(C1からC10アルケニル)フ ェニル、(C1からC10アルキル)ナフチル、(C1からC10アルケニル)ナフチ ル、フェニル(C1からC10アルキル)、フェニル(C1からC10アルケニル)、 ナフチル(C1からC10アルキル)、および、ナフチル(C1からC10アルケニル )であり; R3は、C1からC4アルキル、C1からC4アルケニル、C1からC4アルコキ シ、−OH−SH、−CO2R5、シクロアルキル、シクロアルケニル、ヘテロサイクリ ック、アリール、アルカリール、ヘテロアリール、または、ヘテロアルカリール 、または、これらの組み合わせにより、任意に置換され; R5は、水素原子、C1からC4アルキル、または、C1からC4アルケニル であり; R3には、任意に、酸素原子、窒素原子、イオウ原子、またはこれらの組み あわせが入っていてもよく; R4は、水素原子、C1からC4アルキル、または、C1からC4アルケニルで あり; nは、1から5である)で表わされる化合物; (vi)(b)(i)、(b)(ii)、(b)(iii)、(b)(iv)、および( b)(v)の種々の組み合わせ;または、 (c)(a)と(b)の組み合わせを含有する、組成物。 2. R3が、C1からC4アルキル、C1からC4アルケニル、C1からC4 アルコキシ、−OH、−SH、−CO2R5、またはこれらの組み合わせからなる群から 選択された置換基で置換される、請求項1に記載の組成物。 3. 前記生物学的活性剤が、ペプチド、ムコ多糖、炭水化物、脂質、殺 虫剤、またはこれらの組み合わせから選択される、請求項1に記載の組成物。 4. 前記生物学的活性剤が、ヒト成長ホルモン、ウシ成長ホルモン、成 長ホルモン−放出ホルモン、インターフェロン、インターロイキン−II、インス リン、ヘパリン、カルシトニン、エリスロポイエチン、心房性ナチュレティック (naturetic)因子、抗原、モノクローナル抗体、ソマトスタチン、アドレノコ ルチコトロピン、ゴナドトロピン放出ホルモン、オキシトシン、バソプレッシン 、ナトリウムクロモリン、バンコマイシン、デスフェリオキサミン(DFO)、ま たはこれらの組み合わせから選択される、請求項1に記載の組成物。 5. 前記生物学的活性剤が、インターフェロン、インターロイキン−II 、インスリン、ヘパリン、カルシトニン、オキシトシン、バソプレッシン、ナト リウムクロモリン、バンコマイシン、DFO、またはこれらの組み合わせから選択 される、請求項4に記載の組成物。 6. 前記生物学的活性剤が、カルシトニンである、請求項5に記載の組 成物。 7. 前記アミノ酸が、天然アミノ酸である、請求項1に記載の組成物。 8. 前記アミノ酸が、合成アミノ酸である、請求項1に記載の組成物。 9. 前記アミノ酸が、α−アミノ酸である、請求項1に記載の組成物。 10. 前記アミノ酸が、非α−アミノ酸である、請求項1に記載の組成 物。 11. 前記アミノ酸が、アラニン、アルギニン、アスパラギン、アスパ ラギン酸、シトルリン、システイン、シスチン、グルタミン、グリシン、ヒスチ ジン、イソロイシン、ロイシン、リジン、メチオニン、オルニチン、フェニルア ラニン、フェニルグリシン、プロリン、セリン、スレオニン、トリプトファン= チロシン、バリン、ヒドロキシプロリン、γ−カルボキシグルタマート、O−ホ スホセリン、β−アラニン、α−アミノ酪酸、γ−アミノ酪酸、α−アミノイソ 酪酸、4−(4−アミノフェニル)酪酸、(アミノフェニル)酢酸、アミノ安息 香酸、4−アミノ馬尿酸、(アミノメチル)安息香酸、ε−アミノカプロン酸、 7−アミノヘプタン酸、β−アスパラギン酸、γ−グルタミン酸、システイン( ACM)、ε−リジン、ε−リジン(A−Fmoc)、メチオニン=スルホン、ノルロ イシン、ノルバリン、オルニチン、d−オルニチン、p−ニトロ−フェニルアラニ ン、ヒドロキシ=プロリン、およびチオプロリンからなる群から選択される、請 求項1に記載の組成物。 12. 前記アミノ酸が、アルギニン、ロイシン、リジン、フェニルアラ ニン、チロシン、バリン、フェニルグリシン、4−(4−アミノフェニル)酪酸 、 4−(4−アミノフェニル)酢酸、およびアミノ安息香酸からなる群から選択さ れる、請求項11に記載の組成物。 13. 前記ペプチドが、ジペプチド、トリペプチド、テトラペプチド、 またはペンタペプチドからなる群から選択される、請求項1に記載の組成物。 14. 前記ペプチドが、少なくとも1つの天然アミノ酸を含有する、請 求項1に記載の組成物。 15. 前記ペプチドが、少なくとも1つの合成アミノ酸を含有する、請 求項1に記載の組成物。 16. 前記ペプチドが、少なくとも1つのα−アミノ酸を含有する、請 求項1に記載の組成物。 17. 前記ペプチドが、アラニン、アルギニン、アスパラギン、アスパ ラギン酸、シトルリン、システイン、シスチン、グルタミン、グリシン、ヒスチ ジン、イソロイシン、ロイシン、リジン、メチオニン、オルニチン、フェニルア ラニン、フェニルグリシン、プロリン、セリン、スレオニン、トリプトファン= チロシン、バリン、ヒドロキシプロリン、γ−カルボキシグルタマート、O−ホ スホセリン、β−アラニン、α−アミノ酪酸、γ−アミノ酪酸、α−アミノイソ 酪酸、ε−アミノカプロン酸、7−アミノヘプタン酸、β−アスパラギン酸、γ −グルタミン酸、システイン(ACM)、ε−リジン、ε−リジン(A−Fmoc)、 メチオニン=スルホン、ノルロイシン、ノルバリン、オルニチン、d−オルニチ ン、p−ニトロ−フェニルアラニン、ヒドロキシ=プロリン、およびチオプロリ ンからなる群から選択される1以上のアミノ酸から形成される、請求項1に記載 の組成物。 18. 前記ペプチドが、アルギニン、ロイシン、リジン、フェニルアラ ニン、チロシン、バリン、およびフェニルグリシンからなる群から選択される1 以上のアミノ酸から形成される、請求項17に記載の組成物。 19. 前記アシル化アルデヒドまたはアシル化ケトンは、式:R9−C −X(式中、R9は、アルキル、アルケニル、シクロアルキルまたは芳香族であ り、Xは脱離基である)を有するアシル化剤によってアシル化される、請求項1 に記載の組成物。 20. (A)請求項1に記載の組成物;および (B)(a)付形剤、 (b)希釈剤、 (c)分解剤、 (d)潤滑剤、 (e)かそ剤、 (f)着色剤、 (g)ビヒクル、または (h)これらの組み合わせ を含有する、投与単位製剤。 21. 錠剤、カプセル、または液剤を含有する、請求項20に記載の投 与単位製剤。 22. 生物学的活性剤を必要量動物に投与する方法であって、前記動物 に請求項1に記載の組成物を経口投与することを含有する投与方法。 23. (A)少なくとも1つの生物学的活性剤と; (B)少なくとも1つのキャリアと; (C)任意にビヒクルとを混合することを含有する組成物の調製方法であって 、該キャリアが、 (a)(i)アミノ酸の少なくとも1つのアシル化アルデヒド、 (ii)アミノ酸の少なくとも1つのアシル化ケトン、 (iii)ペプチドの少なくとも1つのアシル化アルデヒド、 (iv)ペプチドの少なくとも1つのアシル化ケトン、または、 (v)(a)(i)、(a)(ii)、(a)(iii)、および(a)(iv)の 種々の組み合わせ; (b)(i)カルボキシメチル−フェニルアラニン−ロイシン、 (ii)2−カルボキシ−3−フェニルプロピオニル−ロイシン、 (iii)2−ベンジルコハク酸、または、 (iv)アクチノニン、または、 (v)式: Ar−Y−(R1)n−OH (式中、Arは、置換または無置換フェニルまたはナフチルであり; Yは、−CO−または−SO2−であり: R1は、−N(R4)−R3−CO−であり; ここで、R3は、C1からC24アルキル、C1からC24アルケニル、フェニル 、ナフチル、(C1からC10アルキル)フェニル、(C1からC10アルケニル)フ ェニル、(C1からC10アルキル)ナフチル、(C1からC10アルケニル)ナフチ ル、フェニル(C1からC10アルキル)、フェニル(C1からC10アルケニル)、 ナフチル(C1からC10アルキル)、および、ナフチル(C1からC10アルケニル )であり; R3は、C1からC4アルキル、C1からC4アルケニル、C1からC4アルコキ シ、−OH、−SH、−CO2R5、シクロアルキル、シクロアルケニル、ヘテロサイク リック、アリール、アルカリール、ヘテロアリール、または、ヘテロアルカリー ル、または、これらの組み合わせにより、任意に置換され; R5は、水素原子、C1からC4アルキル、または、C1からC4アルケニルで あり; R3には、任意に、酸素原子、窒素原子、イオウ原子、またはこれらの組み あわせが入っていてもよく; R4は、水素原子、C1からC4アルキル、または、C1からC4アルケニル であり; nは、1から5である)で表わされる化合物; (vi)(b)(i)、(b)(ii)、(b)(iii)、(b)(iv)、および( b)(v)の種々の組み合わせ;または、 (c)(a)と(b)の組み合わせを含有する、組成物の調製方法。 24. (A)少なくとも1つの生物学的活性剤と; (B)少なくとも1つのキャリアとを含有する薬理学的組成物であって、該キ ャリアが、 (a)(i)アミノ酸の少なくとも1つのアシル化アルデヒド、 (ii)アミノ酸の少なくとも1つのアシル化ケトン、 (iii)ペプチドの少なくとも1つのアシル化アルデヒド、 (iv)ペプチドの少なくとも1つのアシル化ケトン、または、 (v)(a)(i)、(a)(ii)、(a)(iii)、および(a)(iv)の 種々の組み合わせ; (b)(i)カルボキシメチル−フェニルアラニン−ロイシン、 (ii)2−カルボキシ−3−フェニルプロピオニル−ロイシン、 (iii)2−ベンジルコハク酸、または、 (iv)アクチノニン、または、 (v)(b)(i)、(b)(ii)、(b)(iii)、および(b)(iv)の 種々の組み合わせ; (c)(a)と(b)の組み合わせを含有する、薬理学的組成物。 25. 前記生物学的活性剤が、少なくとも1つのペプチド、ムコ多糖、 炭水化物、または、脂質を含有する、請求項24に記載の組成物。 26. 前記生物学的活性剤が、ヒト成長ホルモン、ウシ成長ホルモン、 成長ホルモン−放出ホルモン、インターフェロン、インターロイキン−II、イン スリン、ヘパリン、カルシトニン、エリスロポイエチン、心房性ナチュレティッ ク(naturetic)因子、抗原、モノクローナル抗体、ソマトスタチン、アドレノ コルチコトロピン、ゴナドトロピン放出ホルモン、オキシトシン、バソプレッシ ン、ナトリウムクロモリン、バンコマイシン、デスフェリオキサミン(DFO)、 またはこれらの組み合わせから選択される、請求項25に記載の組成物。 27. 前記生物学的活性剤が、インターフェロン、インターロイキン− II、インスリン、ヘパリン、カルシトニン、オキシトシン、バソプレッシン、バ ンコマイシン、DFO、またはこれらの組み合わせから選択される、請求項26に 記載の組成物。 28. 前記生物学的活性剤が、カルシトニンである、請求項27に記載 の組成物。 29. 前記アミノ酸が、天然アミノ酸である、請求項24に記載の組成 物。 30. 前記アミノ酸が、合成アミノ酸である、請求項24に記載の組成 物。 31. 前記アミノ酸が、α−アミノ酸である、請求項24に記載の組成 物。 32. 前記アミノ酸が、アラニン、アルギニン、アスパラギン、アスパ ラギン酸、シトルリン、システイン、シスチン、グルタミン、グリシン、ヒスチ ジン、イソロイシン、ロイシン、リジン、メチオニン、オルニチン、フェニルア ラニン、フェニルグリシン、プロリン、セリン、スレオニン、トリプトファン= チロシン、バリン、ヒドロキシプロリン、γ−カルボキシグルタマート、O−ホ スホセリン、β−アラニン、α−アミノ酪酸、γ−アミノ酪酸、α−アミノイソ 酪酸、ε−アミノカプロン酸、7−アミノヘプタン酸、β−アスパラギン酸、γ −グルタミン酸、システイン(ACM)、ε−リジン、ε−リジン(A−Fmoc)、 メチオニン=スルホン、ノルロイシン、ノルバリン、オルニチン、d−オルニチ ン、p−ニトロ−フェニルアラニン、ヒドロキシ=プロリン、およびチオプロリ ンからなる群から選択される、請求項24に記載の組成物。 33. 前記アミノ酸が、アルギニン、ロイシン、リジン、フェニルアラ ニン、チロシン、バリン、およびフェニルグリシンからなる群から選択される、 請求項32に記載の組成物。 34. 前記ペプチドが、ジペプチド、トリペプチド、テトラペプチド、 またはペンタペプチドからなる群から選択される、請求項24に記載の組成物。 35. 前記ペプチドが、少なくとも1つの天然アミノ酸を含有する、請 求項24に記載の組成物。 36. 前記ペプチドが、少なくとも1つの合成アミノ酸を含有する、請 求項24に記載の組成物。 37. 前記ペプチドが、少なくとも1つのα−アミノ酸を含有する、請 求項24に記載の組成物。 38. 前記ペプチドが、アラニン、アルギニン、アスパラギン、アスパ ラギン酸、シトルリン、システイン、シスチン、グルタミン、グリシン、ヒスチ ジン、イソロイシン、ロイシン、リジン、メチオニン、オルニチン、フェニルア ラニン、フェニルグリシン、プロリン、セリン、スレオニン、トリプトファン= チロシン、バリン、ヒドロキシプロリン、γ−カルボキシグルタマート、O−ホ スホセリン、β−アラニン、α−アミノ酪酸、γ−アミノ酪酸、α−アミノイソ 酪酸、ε−アミノカプロン酸、7−アミノヘプタン酸、β−アスパラギン酸、γ −グルタミン酸、システイン(ACM)、ε−リジン、ε−リジン(A−Fmoc)、 メチオニン=スルホン、ノルロイシン、ノルバリン、オルニチン、d−オルニチ ン、p−ニトロ−フェニルアラニン、ヒドロキシ=プロリン、およびチオプロリ ンからなる群から選択される1以上のアミノ酸から形成される、請求項24に記 載の組成物。 39. 前記ペプチドが、アルギニン、ロイシン、リジン、フェニルアラ ニン、チロシン、バリン、およびフェニルグリシンからなる群から選択される1 以上のアミノ酸から形成される、請求項38に記載の組成物。 40. 前記アシル化アルデヒドまたはアシル化ケトンは、式:R7−CO −X(式中、R7は、アルキル、シクロアルキル、またはアリールであり、Xは 脱離基である)を有するアシル化剤によってアシル化される、請求項24に記載 の組成物。 41. R7が、メチル、エチル、シクロヘキサン、シクロペンタン、フ ェニル、またはベンジルである、請求項40に記載の組成物。 42. R7が、シクロヘキシル、シクロペンチル、またはシクロヘプチ ル、またはアセチルである、請求項40に記載の組成物。 43. 前記生物学的活性剤が、カルシトニンを含有し、前記キャリアが 、アセチル=フェニルアラニン=アルデヒドおよびカルボメトキシ=フェニルア ラニル−ロイシンを含有する、請求項24に記載の組成物。 44. 前記生物学的活性剤が、1.5μg/mLのカルシトニン、132m g/mlのアセチル=フェニルアラニン=アルデヒド、33mg/mLのカルボメトキ シ=フェニルアラニル−ロイシン、および、25mg/mLのアセチル−Phe−Leu− Leu−Argアルデヒドを含有する、請求項24に記載の組成物。 45. (A)請求項1に記載の薬剤学的組成物;および (B)(a)付形剤、 (b)希釈剤、 (c)分解剤、 (d)潤滑剤、 (e)かそ剤、 (f)着色剤、 (g)ビヒクル、または (h)これらの組み合わせ を含有する、投与単位製剤。 46. 錠剤、カプセル、または液剤を含有する、請求項45に記載の投 与単位製剤。 47. 前記ビヒクルが、水、1,2−プロパンジオール、エタノール、 またはこれらの組み合わせからなる群から選択される、請求項45に記載の投与 単位製剤。 48. 生物学的活性剤を必要量動物に投与する方法であって、前記動物 に請求項25に記載の組成物を経口投与することを含有する投与方法。 49. (A)少なくとも1つの生物学的活性剤と; (B)キャリアと; (C)任意にビヒクルとを混合することを含有する薬剤学的組成物の調製方法 であって、該キャリアが、 (a)(i)アミノ酸の少なくとも1つのアシル化アルデヒド、 (ii)アミノ酸の少なくとも1つのアシル化ケトン、 (iii)ペプチドの少なくとも1つのアシル化アルデヒド、 (iv)ペプチドの少なくとも1つのアシル化ケトン、または、 (v)(a)(i)、(a)(ii)、(a)(iii)、および(a)(iv)の 種々の組み合わせ; (b)(i)カルボキシメチル−フェニルアラニン−ロイシン、 (ii)2−カルボキシ−3−フェニルプロピオニル−ロイシン、 (iii)2−ベンジルコハク酸、または、 (iv)4−(フェニルスルホンアミド)−4−フェニル酪酸、または、 (v)(b)(i)、(b)(ii)、(b)(iii)、および(b)(iv)の 種々の組み合わせ;または、 (c)(a)と(b)の組み合わせを含有する、組成物の調製方法。 50. N−シクロヘキサノイルフェニルアラニンアルデヒド化合物。 51. 活性剤とアミノ酸アミドまたはスルホンアミドを含有する1以上 の修飾アミノ酸を含有する組成物。 52. 前記修飾アミノ酸が、2以上のアミノ酸アミドまたはスルホンア ミドを含有する、請求項51に記載の組成物。 53. 前記修飾アミノ酸が、アミノ酸と、塩化ベンゼンスルホニル、塩 化ベンゾイル、塩化ヒップリル、またはアミノ酸カルボジイミドを含有するアミ ノ反応性修飾剤との反応によって誘導される、請求項51に記載の組成物。 54. 前記生物学的活性剤が、ヒトまたはウシ成長ホルモン、インター フェロン、インターロイキン−II、インスリン、カルシトニン、エリスロポイエ チン、心房性ナチュレティック(naturetic)因子、抗原、または、モノクロー ナル抗体を含有する、請求項51に記載の組成物。 55. 修飾アミノ酸微球体内にカプセル化された活性剤を含有する組成 物であって、前記微球体が少なくとも1つのアミノ酸アミドまたはスルホンアミ ドの壁を含有する、組成物。 56. 前記アミノ酸アミドまたはスルホンアミドが、アミノ酸のベンゼ ンアミドまたはベンゼンスルホンアミドを含有する、請求項55に記載の組成物 。 57. 前記生物学的活性剤が、ヒトまたはウシ成長ホルモン、インター フェロン、インターロイキン−II、インスリン、カルシトニン、エリスロポイエ チン、心房性ナチュレティック(naturetic)因子、抗原、または、モノクロー ナル抗体を含有する、請求項55に記載の組成物。 58. 修飾アミノ酸微球体の調製方法であって、 (a)修飾アミノ酸微球体を形成すべく、少なくとも1つ以上のアミノ酸ア ミドまたはスルホンアミドを酸水溶液中でインキュベートする工程と; (b)前記修飾アミノ酸微球体を収集する工程とを含有する、修飾アミノ酸 微球体の調製方法。 59. 前記アミノ酸アミドまたはスルホンアミドが、アミノ酸と、塩化 ベンゼンスルホニル、塩化ベンゾイル、塩化ヒップリル、またはアミノ酸カルボ ジイミドを含有するアミノ反応性修飾剤との反応によって誘導される、請求項5 8に記載の方法。 60. 前記酸水溶液が生物学的活性剤をさらに含有する、請求項58に 記載の方法。 61. 前記生物学的活性剤が、ヒトまたはウシ成長ホルモン、インター フェロン、インターロイキン−II、インスリン、カルシトニン、エリスロポイエ チン、心房性ナチュレティック(naturetic)因子、抗原、または、モノクロー ナル抗体を含有する、請求項60に記載の方法。 62. 前記アミノ酸またはペプチドが、式:R7−CO−X(式中、R7 は、アルキル、アルケニル、または芳香族であり、Xは脱離基である)を有する アシル化剤によってアシル化される、請求項1に記載の組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/051,019 US5451410A (en) | 1993-04-22 | 1993-04-22 | Modified amino acids for encapsulating active agents |
US051,019 | 1993-04-22 | ||
US205,511 | 1994-03-02 | ||
US08/205,511 US5792451A (en) | 1994-03-02 | 1994-03-02 | Oral drug delivery compositions and methods |
PCT/US1994/004560 WO1994023767A1 (en) | 1993-04-22 | 1994-04-22 | Oral drug delivery compositions and methods |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006192105A Division JP4657164B2 (ja) | 1993-04-22 | 2006-07-12 | 経口薬剤移送組成物およびその方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08509474A true JPH08509474A (ja) | 1996-10-08 |
JP4361601B2 JP4361601B2 (ja) | 2009-11-11 |
Family
ID=26728964
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52359594A Expired - Lifetime JP4361601B2 (ja) | 1993-04-22 | 1994-04-22 | 経口薬剤移送組成物およびその方法 |
JP2006192105A Expired - Lifetime JP4657164B2 (ja) | 1993-04-22 | 2006-07-12 | 経口薬剤移送組成物およびその方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006192105A Expired - Lifetime JP4657164B2 (ja) | 1993-04-22 | 2006-07-12 | 経口薬剤移送組成物およびその方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US5766633A (ja) |
EP (3) | EP1077070A3 (ja) |
JP (2) | JP4361601B2 (ja) |
AT (2) | ATE204467T1 (ja) |
AU (1) | AU6819294A (ja) |
CA (1) | CA2160693C (ja) |
DE (2) | DE69434418T2 (ja) |
ES (2) | ES2163444T3 (ja) |
IL (1) | IL109403A0 (ja) |
WO (1) | WO1994023767A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005510535A (ja) * | 2001-11-29 | 2005-04-21 | エミスフィアー テクノロジーズ インコーポレイテッド | クロモリンナトリウムの経口投与用製剤 |
JP2007537301A (ja) * | 2004-05-14 | 2007-12-20 | エミスフェアー・テクノロジーズ・インク | 活性薬剤を送達するための化合物および組成物 |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5578323A (en) | 1992-06-15 | 1996-11-26 | Emisphere Technologies, Inc. | Proteinoid carriers and methods for preparation and use thereof |
US6331318B1 (en) * | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
US5447728A (en) * | 1992-06-15 | 1995-09-05 | Emisphere Technologies, Inc. | Desferrioxamine oral delivery system |
US6916489B2 (en) * | 1992-06-15 | 2005-07-12 | Emisphere Technologies, Inc. | Active agent transport systems |
US5981719A (en) | 1993-03-09 | 1999-11-09 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US6090925A (en) | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
DE69434418T2 (de) * | 1993-04-22 | 2005-12-22 | Emisphere Technologies, Inc. | Orale Dareichungsform |
US5709861A (en) * | 1993-04-22 | 1998-01-20 | Emisphere Technologies, Inc. | Compositions for the delivery of antigens |
US5643957A (en) * | 1993-04-22 | 1997-07-01 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US20010003001A1 (en) * | 1993-04-22 | 2001-06-07 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US6610329B2 (en) * | 1993-04-22 | 2003-08-26 | Emisphere Technologies Inc. | Compositions for the delivery of antigens |
DE69636983T2 (de) * | 1995-03-31 | 2008-01-03 | Emisphere Technologies, Inc. | Stoffe und zusammensetzungen für die verabreichung aktiver substanzen |
KR100489667B1 (ko) * | 1995-03-31 | 2006-01-12 | 에미스페어 테크놀로지스, 인코포레이티드 | 활성제전달용화합물및조성물 |
US6001347A (en) | 1995-03-31 | 1999-12-14 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5650386A (en) * | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
EP1792624A1 (en) * | 1995-03-31 | 2007-06-06 | Emisphere Technologies, Inc. | Modified amino acids and compositions comprising them for delivering active agents |
US5667806A (en) * | 1995-06-07 | 1997-09-16 | Emisphere Technologies, Inc. | Spray drying method and apparatus |
AU2595697A (en) | 1996-03-29 | 1997-10-22 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US6391303B1 (en) | 1996-11-18 | 2002-05-21 | Emisphere Technologies, Inc. | Methods and compositions for inducing oral tolerance in mammals |
US6313088B1 (en) | 1997-02-07 | 2001-11-06 | Emisphere Technologies, Inc. | 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents |
US6358504B1 (en) | 1997-02-07 | 2002-03-19 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
JPH11279040A (ja) | 1998-03-27 | 1999-10-12 | Kao Corp | 皮膚外用剤 |
DE69925276T2 (de) | 1998-07-27 | 2005-10-06 | Emisphere Technologies, Inc. | Stoffe und zusammensetzungen für die verabreichung aktiver substanzen |
US6440929B1 (en) | 1998-07-27 | 2002-08-27 | Emisphere Technologies, Inc. | Pulmonary delivery of active agents |
US6991798B1 (en) | 1998-08-07 | 2006-01-31 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
DE69931930T2 (de) * | 1998-08-07 | 2006-10-05 | Emisphere Technologies, Inc. | Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen |
NZ512581A (en) | 1999-01-08 | 2002-12-20 | Univ Virginia Commonwealth | Polymeric delivery agents comprising a polymer conjugated to a modified amino acid and derivatives thereof |
US7084279B1 (en) | 1999-02-11 | 2006-08-01 | Emisphere Technologies Inc. | Oxadiazole compounds and compositions for delivering active agents |
CA2364849A1 (en) | 1999-02-26 | 2000-08-31 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
AU4216700A (en) * | 1999-04-05 | 2000-10-23 | Emisphere Technologies, Inc. | Disodium salts, monohydrates, and ethanol solvates |
US6346264B1 (en) * | 1999-04-27 | 2002-02-12 | International Health Products And Services Ltd. | Supplement for restoring growth hormone levels |
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
US6375948B1 (en) | 1999-07-12 | 2002-04-23 | Kao Corporation | Treating method for suppressing hair growth |
US7129274B1 (en) | 1999-11-05 | 2006-10-31 | Emisphere Technologies Inc. | Phenoxy carboxylic acid compounds and compositions for delivering active agents |
US7279597B1 (en) | 1999-11-05 | 2007-10-09 | Emisphere Technologies, Inc. | Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
JP4850379B2 (ja) * | 1999-12-16 | 2012-01-11 | エミスフェアー・テクノロジーズ・インク | 活性剤を輸送するための化合物及び組成物 |
US7151191B2 (en) * | 2000-01-13 | 2006-12-19 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
DE60133555T2 (de) | 2000-06-29 | 2008-09-18 | Emisphere Technologies, Inc. | Verbindungen und gemische zur verabreichung eines aktiven agens |
CN1313441C (zh) | 2000-09-06 | 2007-05-02 | 艾米斯菲尔技术有限公司 | 用于递送活性剂的氰基苯氧基羧酸化合物及其组合物 |
EP1315513B1 (en) * | 2000-09-08 | 2011-03-09 | Amylin Pharmaceuticals, Inc. | "pseudo"-native chemical ligation |
NZ527026A (en) | 2001-03-01 | 2006-01-27 | Emisphere Tech Inc | Compounds and compositions for delivering active agents |
US20030225300A1 (en) * | 2001-04-19 | 2003-12-04 | Emisphere Technologies Inc. | Compounds and compositions for delivering active agents |
US7008650B2 (en) * | 2001-08-09 | 2006-03-07 | Lam Paul Y S | Compositions for the treatment of acquired immunodeficiency disease |
CA2471144C (en) | 2002-01-09 | 2011-06-07 | Emisphere Technologies, Inc. | Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate |
MXPA04008068A (es) | 2002-02-20 | 2004-11-26 | Lilly Co Eli | Metodo para administrar moleculas de glp-1. |
DE60318938T2 (de) | 2002-03-20 | 2009-01-22 | Mannkind Corp., Valencia | Inhalationsgerät |
WO2004104018A2 (en) * | 2003-05-14 | 2004-12-02 | Emisphere Technologies, Inc. | Compositions for delivering peptide yy and pyy agonists |
FR2855521B1 (fr) * | 2003-05-28 | 2005-08-05 | Flamel Tech Sa | Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques. |
US20060286129A1 (en) * | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
US7217703B2 (en) * | 2004-04-16 | 2007-05-15 | Emisphere Technologies, Inc. | 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents |
CA2566161C (en) * | 2004-05-14 | 2013-10-01 | Emisphere Technologies, Inc. | Aryl ketone compounds and compositions for delivering active agents |
CN1968704B (zh) | 2004-05-19 | 2010-12-08 | 爱密斯菲尔科技公司 | 局部用色甘酸制剂 |
JP5122954B2 (ja) | 2004-05-19 | 2013-01-16 | エミスフェアー・テクノロジーズ・インク | アシクロビル製剤 |
CN101014360A (zh) | 2004-08-03 | 2007-08-08 | 埃米斯菲尔技术公司 | 抗糖尿病口服胰岛素-双胍组合物 |
US20060078622A1 (en) * | 2004-08-13 | 2006-04-13 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
ES2385934T3 (es) | 2004-08-20 | 2012-08-03 | Mannkind Corporation | Catálisis de la síntesis de dicetopiperazina. |
EP2314298B1 (en) | 2004-08-23 | 2015-05-27 | MannKind Corporation | Microparticles comprising diketopiperazine salts for drug delivery |
ES2535311T3 (es) | 2004-12-29 | 2015-05-08 | Emisphere Technologies, Inc. | Formulaciones farmacéuticas de sales de galio |
US8975227B2 (en) | 2005-07-15 | 2015-03-10 | Emisphere Technologies, Inc. | Intraoral dosage forms of glucagon |
JP5173807B2 (ja) * | 2005-08-19 | 2013-04-03 | エミスフェアー・テクノロジーズ・インク | 活性剤を送達するためのシクロプロピル化合物および組成物 |
US20070049557A1 (en) * | 2005-08-24 | 2007-03-01 | Hashim Ahmed | Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers |
KR20160022404A (ko) | 2005-09-14 | 2016-02-29 | 맨카인드 코포레이션 | 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법 |
MX2008010721A (es) | 2006-02-22 | 2008-09-01 | Mannkind Corp | Un metodo para mejorar las propiedades farmaceuticas de microparticulas que contienen dicetopiperazina y un agente activo. |
US8927015B2 (en) | 2006-04-12 | 2015-01-06 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
US8703821B2 (en) * | 2006-04-18 | 2014-04-22 | Emisphere Technologies Inc. | Dialkyl ether delivery agents |
CA2656019C (en) * | 2006-06-28 | 2016-09-13 | Emisphere Technologies, Inc. | Gallium nitrate formulations |
ES2745411T3 (es) | 2006-07-27 | 2020-03-02 | Wang Nai Fang | Compuestos y composiciones de arilsulfanilo para administración de agentes activos |
EP2053918B1 (en) | 2006-08-18 | 2014-07-23 | Emisphere Technologies, Inc. | Propyl phenoxy ethers for use as delivery agents |
USRE48164E1 (en) | 2006-08-31 | 2020-08-18 | Emisphere Technologies Inc. | Compounds and compositions for delivering active agents |
MX340993B (es) | 2007-02-08 | 2016-08-02 | Emisphere Tech Inc * | Agentes de suministro de acido fenilalquilcarboxilico. |
WO2008101240A1 (en) * | 2007-02-16 | 2008-08-21 | Emisphere Technologies, Inc. | Compounds having a cyclic moiety and compositions for delivering active agents |
EP3050568B1 (en) | 2007-03-13 | 2020-12-02 | JDS Therapeutics, LLC | Methods and compositions for the sustained release of chromium |
WO2008116141A1 (en) | 2007-03-21 | 2008-09-25 | Emisphere Technologies, Inc. | Allylqxy and alkyloxy benzoic acid delivery agents |
US20080260823A1 (en) * | 2007-04-20 | 2008-10-23 | Sciele Pharma, Inc. | Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea |
WO2009002867A2 (en) | 2007-06-26 | 2008-12-31 | Nutrition 21, Inc. | Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement |
EP2187915B1 (en) * | 2007-09-11 | 2011-08-31 | Mondobiotech Laboratories AG | Use of the peptide phpfhlfvy (renin inhibitor) in anti-angiogenic therapy of certain diseases |
EP3281663B8 (en) | 2008-06-13 | 2022-09-21 | MannKind Corporation | Breath powered dry powder inhaler for drug delivery |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
MX2010014240A (es) | 2008-06-20 | 2011-03-25 | Mankind Corp | Un metodo y aparato interactivo para perfilar en tiempo real esfuerzos de inhalacion. |
TWI614024B (zh) | 2008-08-11 | 2018-02-11 | 曼凱公司 | 超快起作用胰島素之用途 |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
CA2754595C (en) | 2009-03-11 | 2017-06-27 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
EP2236617A1 (en) * | 2009-03-31 | 2010-10-06 | Leukocare Ag | Methods of terminal sterilization of biofunctional compositions |
US8551528B2 (en) | 2009-06-12 | 2013-10-08 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
US20110039930A1 (en) | 2009-08-03 | 2011-02-17 | Emisphere Technologies, Inc. | Fast-acting naproxen composition with reduced gastrointestinal effects |
EP2496295A1 (en) | 2009-11-03 | 2012-09-12 | MannKind Corporation | An apparatus and method for simulating inhalation efforts |
BR112012033060A2 (pt) | 2010-06-21 | 2018-02-27 | Mannkind Corp | métodos de sistema de liberação de fármaco em pó seco |
ES2927800T3 (es) | 2011-03-01 | 2022-11-11 | Nutrition 21 Llc | Composición de insulina y cromo para el tratamiento y la prevención de diabetes, hipoglicemia y trastornos relacionados |
KR101940832B1 (ko) | 2011-04-01 | 2019-01-21 | 맨카인드 코포레이션 | 의약 카트리지용 블리스터 패키지 |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
EP2776053A1 (en) | 2011-10-24 | 2014-09-17 | MannKind Corporation | Methods and compositions for treating pain |
SG11201500218VA (en) | 2012-07-12 | 2015-03-30 | Mannkind Corp | Dry powder drug delivery systems and methods |
US9458089B2 (en) | 2012-08-23 | 2016-10-04 | Emisphere Technologies, Inc. | Phenoxy alkyl diethanolamine and diisopropanolamine compounds for delivering active agents |
JP6374388B2 (ja) | 2012-09-21 | 2018-08-15 | インテンシティ セラピューティクス, インク.Intensity Therapeutics, Inc. | 癌の治療方法 |
EP2911690A1 (en) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Inhalable influenza vaccine compositions and methods |
EP3587404B1 (en) | 2013-03-15 | 2022-07-13 | MannKind Corporation | Microcrystalline diketopiperazine compositions, methods for preparation and use thereof |
BR122019026637B1 (pt) | 2013-07-18 | 2023-09-26 | Mannkind Corporation | Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco |
CA2920488C (en) | 2013-08-05 | 2022-04-26 | Mannkind Corporation | Insufflation apparatus and methods |
WO2015148905A1 (en) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
CN107847552B (zh) | 2015-01-07 | 2022-07-01 | 三叉神经股份公司 | 含镁的催产素制剂和使用方法 |
GB2564295A (en) | 2016-02-11 | 2019-01-09 | Nutrition 21 Llc | Chromium containing compositions for improving health and fitness |
Family Cites Families (136)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US24899A (en) * | 1859-07-26 | Edwabd f | ||
US2671451A (en) * | 1952-06-16 | 1954-03-09 | Stephen J Bolger | Remedial pill |
NL95044C (ja) | 1953-06-30 | |||
US2868740A (en) * | 1954-03-25 | 1959-01-13 | Swift & Co | Method of copolymerizing acrylic or methacrylic acid with proteinaceous material and product obtained |
US2862918A (en) * | 1956-03-12 | 1958-12-02 | Glidden Co | Acylated, isolated, partially-hydrolyzed, soya protein and process |
NL108169C (ja) * | 1957-01-30 | |||
US3057344A (en) * | 1957-05-21 | 1962-10-09 | Abella Carlos Alberto | Capsule for the study of the digestive tract and method of using the same |
US3016308A (en) * | 1957-08-06 | 1962-01-09 | Moore Business Forms Inc | Recording paper coated with microscopic capsules of coloring material, capsules and method of making |
US3052655A (en) * | 1958-08-01 | 1962-09-04 | Sidney W Fox | Thermal polymerization of amino acid mixtures containing aspartic acid or a thermal precursor of aspartic acid |
US3076790A (en) * | 1958-08-01 | 1963-02-05 | Sidney W Fox | Method of making copolymers of amino acids containing glutamic acid |
FR1351358A (fr) | 1958-12-22 | 1964-02-07 | Ncr Co | Procédé de formation de revêtements imperméables pour des matières en particules par séparation de phases liquides |
FR1468601A (fr) | 1958-12-22 | 1967-02-10 | Ncr Co | Procédé de formation d'enduits protecteurs pour des particules solides et liquides |
GB929401A (en) | 1958-12-22 | 1963-06-19 | Upjohn Co | Encapsulated emulsions and processes for their preparation |
NL246985A (ja) * | 1958-12-31 | |||
US3170802A (en) * | 1960-12-14 | 1965-02-23 | Zh Noda Sangyo Kagaku Kenkyush | Method for treatment of soybean proteins |
GB1075952A (en) | 1962-12-31 | 1967-07-19 | Gelatine And Glue Res Ass | Microscopic capsules and methods of making them |
US3748277A (en) * | 1965-10-14 | 1973-07-24 | Ncr Co | Process of forming minute capsules |
US3474777A (en) * | 1966-02-10 | 1969-10-28 | Amp Inc | Method of administering therapeutic agents |
US3576758A (en) * | 1966-10-17 | 1971-04-27 | Ncr Co | Treatment of polypeptide-containing hydrophilic polymeric capsule wall material with uranium and vanadium compounds |
FR7981M (ja) * | 1967-10-21 | 1970-06-08 | ||
US3491093A (en) * | 1967-11-29 | 1970-01-20 | Endo Lab | Derivatives of 5 aminomethyl-4,5,6,7-tetrahydro-4-oxoindoles |
US3565559A (en) * | 1968-03-11 | 1971-02-23 | Sumitomo Chemical Co | Process for making microcapsules |
US3574832A (en) * | 1968-05-29 | 1971-04-13 | American Cyanamid Co | Therapeutic heparin-surfactant compositions |
US3567650A (en) * | 1969-02-14 | 1971-03-02 | Ncr Co | Method of making microscopic capsules |
US3937668A (en) * | 1970-07-15 | 1976-02-10 | Ilse Zolle | Method for incorporating substances into protein microspheres |
US3725113A (en) * | 1970-12-17 | 1973-04-03 | Research Corp | Blood compatible microencapsulated detoxicants and method for making |
US3822348A (en) * | 1970-12-28 | 1974-07-02 | Toyo Jozo Kk | Hormone-like substance having serum calcium reducing property |
US3962416A (en) * | 1971-01-25 | 1976-06-08 | Sol Katzen | Preserved nutrients and products |
IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
US3794561A (en) * | 1971-09-30 | 1974-02-26 | Sasaki T | Biologically active peptide and method of preparing the same |
US3816404A (en) * | 1971-12-08 | 1974-06-11 | Texaco Inc | Preparation of caprolactam |
US3933873A (en) * | 1971-12-08 | 1976-01-20 | Texaco Inc. | Preparation of omega-aminoalkanoic acids |
US3795739A (en) * | 1972-02-14 | 1974-03-05 | Hoffmann La Roche | Treatment of parkinson disease |
JPS5210427B2 (ja) * | 1972-07-19 | 1977-03-24 | ||
CA1045977A (en) | 1973-05-17 | 1979-01-09 | Arthur D. Little | Biodegradable, implantable drug delivery device, and process for preparing and using the same |
US4450150A (en) * | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
US4351337A (en) * | 1973-05-17 | 1982-09-28 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery device, and process for preparing and using the same |
DE2343037A1 (de) | 1973-08-25 | 1975-03-06 | Hoechst Ag | Arzneimittel mit antidepressiver wirkung |
US3939253A (en) * | 1973-11-02 | 1976-02-17 | Interx Research Corporation | Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease |
GB1459488A (en) * | 1974-03-19 | 1976-12-22 | Wyeth John & Brother Ltd | Piperazinedione derivatives |
US4061466A (en) * | 1974-10-16 | 1977-12-06 | Ingvar Gosta Holger Sjoholm | Biologically active composition and the use thereof |
US4183849A (en) * | 1975-01-15 | 1980-01-15 | Nordisk Insulinlaboratorium | Therapeutic insulin preparation and a process for the production of a stable insulin preparation with protracted effect |
US4048268A (en) * | 1975-02-19 | 1977-09-13 | Eli Lilly And Company | Stabilization method |
US4035507A (en) * | 1975-04-17 | 1977-07-12 | Interx Research Corporation | Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease |
CA1077842A (en) | 1975-10-09 | 1980-05-20 | Minnesota Mining And Manufacturing Company | Albumin medicament carrier system |
US4405598A (en) * | 1976-01-30 | 1983-09-20 | Fisons, Limited | Composition for treating asthma |
US4117801A (en) * | 1976-06-10 | 1978-10-03 | Eastman Kodak Company | Apparatus for spray coating discrete particles |
US4357259A (en) * | 1977-08-01 | 1982-11-02 | Northwestern University | Method of incorporating water-soluble heat-sensitive therapeutic agents in albumin microspheres |
US4217370A (en) * | 1977-08-25 | 1980-08-12 | Blue Wing Corporation | Lipid-containing feed supplements and foodstuffs |
US4199561A (en) * | 1979-02-26 | 1980-04-22 | The Dow Chemical Company | Coated nutrients and medicaments for veterinary use |
US4352883A (en) * | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
US4345588A (en) * | 1979-04-23 | 1982-08-24 | Northwestern University | Method of delivering a therapeutic agent to a target capillary bed |
US4272506A (en) * | 1979-08-31 | 1981-06-09 | Syva Company | Purification of reagents by disulfide immobilization |
HU181009B (en) * | 1980-01-18 | 1983-05-30 | Richter Gedeon Vegyeszet | Process for preparing angiotensin-ii analogues with antagonictic activity containing in position 1 sarcosyl,hydroxyacetyl or l-alpha-aminoxy-propionyl group and in positiona 8 esteric group |
NZ196349A (en) * | 1980-03-07 | 1984-08-24 | Interx Research Corp | Enhancement of absorption rate of orally administered polar bioactive agents |
IT1148784B (it) * | 1980-04-09 | 1986-12-03 | Eurand Spa | Procedimento per la preparazione di microcapsule in un veicolo liquido |
DE3016170A1 (de) * | 1980-04-26 | 1981-10-29 | Bayer Ag, 5090 Leverkusen | Mikrokapseln mit definierter oeffnungstemperatur, verfahren zu deren herstellung sowie deren verwendung |
US4289759A (en) * | 1980-06-23 | 1981-09-15 | Ortho Pharmaceutical Corporation | Immunoregulatory diketopiperazine compounds |
US4348384A (en) * | 1980-10-17 | 1982-09-07 | Dainippon Pharmaceutical Co., Ltd. | Pharmaceutical composition for oral administration containing coagulation factor VIII or IX |
US4442090A (en) * | 1980-11-09 | 1984-04-10 | Kyoto Yakuhin Kogyo Kabushiki Kaisha | Absorption-promoting compounds, compositions thereof with pharmaceuticals and/or bases for rectal administration and method of use |
US4900730A (en) * | 1981-01-14 | 1990-02-13 | Toyo Jozo Co., Ltd. | Preparation which promotes the absorption of peptides |
GB2092136B (en) * | 1981-01-17 | 1985-06-05 | Mitsui Toatsu Chemicals | Production of n-substituted amide compounds |
US4483807A (en) * | 1981-01-27 | 1984-11-20 | Japan Atomic Energy Research Institute | Process for producing a slow release composite |
JPS58140026A (ja) * | 1982-01-14 | 1983-08-19 | Toyo Jozo Co Ltd | 吸収性良好な製剤 |
FR2509175B1 (fr) * | 1981-03-06 | 1987-01-16 | Toyo Jozo Kk | Preparation therapeutique ayant d'excellentes proprietes d'absorption |
JPS57146721A (en) * | 1981-03-06 | 1982-09-10 | Toyo Jozo Co Ltd | Improver for absorption |
NZ201010A (en) | 1981-06-19 | 1986-02-21 | Ciba Geigy Ag | The treatment of inflammation diseases using desferrioxamine |
US4446138A (en) * | 1982-02-10 | 1984-05-01 | Pack Howard M | Method and composition for reducing weight |
CA1241646A (en) * | 1982-02-22 | 1988-09-06 | Adolfo J. De Bold | Atrial natriuretic factor |
US4518433A (en) * | 1982-11-08 | 1985-05-21 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
US4473620A (en) * | 1982-12-23 | 1984-09-25 | Eastman Kodak Company | Encapsulated butylated hydroxyanisole |
US4886663A (en) * | 1983-01-03 | 1989-12-12 | Scripps Clinic And Research Foundation | Synthetic heat-stable enterotoxin polypeptide of Escherichia coli and multimers thereof |
JPS59163313A (ja) * | 1983-03-09 | 1984-09-14 | Teijin Ltd | 経鼻投与用ペプチドホルモン類組成物 |
CA1196862A (en) * | 1983-06-01 | 1985-11-19 | Anthony M.F. Sun | Microencapsulation of living tissue and cells |
CA1196863A (en) * | 1983-06-08 | 1985-11-19 | Mattheus F.A. Goosen | Slow release injectable insulin composition |
US4462839A (en) * | 1983-06-16 | 1984-07-31 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
US4608278A (en) * | 1983-06-22 | 1986-08-26 | The Ohio State University Research Foundation | Small particule formation and encapsulation |
US4671954A (en) * | 1983-12-13 | 1987-06-09 | University Of Florida | Microspheres for incorporation of therapeutic substances and methods of preparation thereof |
US4590265A (en) * | 1984-02-17 | 1986-05-20 | Eastman Kodak Company | Carboxylated cellulose ester and manufacture thereof |
JPS60176549A (ja) * | 1984-02-22 | 1985-09-10 | Nisshin Oil Mills Ltd:The | たん白分解物の製造法 |
US4703042A (en) * | 1984-05-21 | 1987-10-27 | Bodor Nicholas S | Orally active heparin salts containing multivalent cationic units |
FR2565102B1 (fr) | 1984-06-05 | 1987-03-20 | Paris Sud Universite | Microcapsules biodegradables a base de serumalbumine, leur preparation et leur application a la liberation in situ de medicuments |
US4757066A (en) * | 1984-10-15 | 1988-07-12 | Sankyo Company Limited | Composition containing a penem or carbapenem antibiotic and the use of the same |
IT1177384B (it) * | 1984-12-12 | 1987-08-26 | Boeehringer Biochemia Robin Sp | Prodotti dietetici granulari a base di amminoacidi e procedimento per la loro preparazione |
US4708952A (en) * | 1985-02-06 | 1987-11-24 | Aida Salatinjants | Method of treatment of the infectious and viral diseases by one time interference |
CS254355B1 (en) * | 1985-04-10 | 1988-01-15 | Vladimir Saudek | Soluble and biodegradatable copolymeres activated for bond of biologicaly active substances |
US4897444A (en) * | 1985-05-31 | 1990-01-30 | The Research Foundation Of The State University Of New York | Immobilized fluorogenic substrates for enzymes; and processes for their preparation |
US4757024A (en) * | 1985-05-31 | 1988-07-12 | Biostar Medical Products, Inc. | Immune complex detection method and article using immunologically non-specific immunoglobulins |
US4789734A (en) * | 1985-08-06 | 1988-12-06 | La Jolla Cancer Research Foundation | Vitronectin specific cell receptor derived from mammalian mesenchymal tissue |
IT1214629B (it) * | 1985-08-29 | 1990-01-18 | Formenti Farmaceutici Spa | Procedimento di microincapsulazione di un medicamento,medicamento cosi'preparato,e composizioni farmaceutiche che lo comprendono |
DE3682257D1 (de) * | 1985-11-22 | 1991-12-05 | Takeda Chemical Industries Ltd | Liposomzusammensetzung. |
IT1188550B (it) * | 1986-02-07 | 1988-01-14 | Sclavo Spa | Peptide sintetico ad attivita' interleukina 1 umana |
US4919939A (en) * | 1986-04-29 | 1990-04-24 | Pharmetrix Corporation | Periodontal disease treatment system |
US4837381A (en) * | 1986-08-11 | 1989-06-06 | American Cyanamid Company | Compositions for parenteral administration and their use |
JP2765700B2 (ja) | 1986-08-11 | 1998-06-18 | イノベータ・バイオメド・リミテツド | マイクロカプセルを含有する医薬調合物 |
EP0545913B1 (en) * | 1986-08-18 | 1999-02-24 | Emisphere Technologies, Inc. | Delivery systems for pharmacological agents |
DE3700128A1 (de) * | 1987-01-03 | 1988-07-14 | Hoechst Ag | Biologisch abbaubare poly- (hydroxyalkyl)- aminodicarbonsaeure-derivate, verfahren zu ihrer herstellung und verwendung derselben fuer depotzubereitungen mit kontrollierter wirkstoffabgabe |
US5077278A (en) * | 1987-01-23 | 1991-12-31 | Pfizer Inc. | Non-natural demethylavermectins compositions and method of use |
US5069936A (en) * | 1987-06-25 | 1991-12-03 | Yen Richard C K | Manufacturing protein microspheres |
MX12394A (es) | 1987-07-23 | 1993-12-01 | Ciba Geigy Ag | Procedimiento par la obtencion de carbamatos de polietilenglicol. |
US4895725A (en) * | 1987-08-24 | 1990-01-23 | Clinical Technologies Associates, Inc. | Microencapsulation of fish oil |
US5067961A (en) * | 1988-02-18 | 1991-11-26 | Autogenesis Technologies, Inc. | Non-biodegradable two phase corneal implant and method for preparing same |
JP2670680B2 (ja) * | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
US5055300A (en) * | 1988-06-17 | 1991-10-08 | Basic Bio Systems, Inc. | Time release protein |
FR2636238B1 (fr) * | 1988-09-14 | 1994-01-21 | Morelle Jean | Nouvelles compositions antisudorales |
GB8822857D0 (en) | 1988-09-29 | 1988-11-02 | Patralan Ltd | Pharmaceutical formulations |
GB8823731D0 (en) | 1988-10-10 | 1988-11-16 | Smith Kline French Lab | Biologically active compounds |
US5039481A (en) * | 1988-12-16 | 1991-08-13 | Clean Air, Inc. | Aliphatic polycarboxylic acids as air purification compositions |
US4976968A (en) * | 1989-02-24 | 1990-12-11 | Clinical Technologies Associates, Inc. | Anhydrous delivery systems for pharmacological agents |
US4983402A (en) * | 1989-02-24 | 1991-01-08 | Clinical Technologies Associates, Inc. | Orally administerable ANF |
CA2012306A1 (en) | 1989-03-28 | 1990-09-28 | Werner Neidhart | Amino acid derivatives |
US5122367A (en) * | 1989-03-31 | 1992-06-16 | Massachusetts Institute Of Technology | Polyanhydride bioerodible controlled release implants for administration of stabilized growth hormone |
US4963364A (en) * | 1989-04-10 | 1990-10-16 | Fox Sidney W | Microencapsulated antitumor agent |
US5100918A (en) * | 1989-05-25 | 1992-03-31 | Sterling Drug, Inc. | Prevention or treatment of sunburn using the S(+) isomer of ibuprofen |
US4996292A (en) * | 1989-06-30 | 1991-02-26 | Fox Sidney W | Self-sealing artificial skin comprising copoly-alpha-amino acid |
JP2911496B2 (ja) | 1989-09-11 | 1999-06-23 | 帝國製薬株式会社 | 生理活性ポリペプチド含有高吸収性経膣剤 |
US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
US5216124A (en) | 1989-12-15 | 1993-06-01 | G. D. Searle & Co. | Substituted cyclic tetrapeptides |
US5126147A (en) | 1990-02-08 | 1992-06-30 | Biosearch, Inc. | Sustained release dosage form |
FR2658076B1 (fr) | 1990-02-12 | 1992-06-12 | Sanofi Sa | Composition cosmetique contenant des copolymeres d'aminoacides, utile comme agent hydratant. |
JP3249147B2 (ja) | 1990-06-01 | 2002-01-21 | キリン−アムジエン・インコーポレーテツド | 生理活性蛋白含有経口製剤 |
CA2046830C (en) | 1990-07-19 | 1999-12-14 | Patrick P. Deluca | Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer |
US5451410A (en) | 1993-04-22 | 1995-09-19 | Emisphere Technologies, Inc. | Modified amino acids for encapsulating active agents |
JPH05239021A (ja) | 1990-09-04 | 1993-09-17 | Microbial Chem Res Found | 新規なアクチノニン誘導体 |
US5418010A (en) | 1990-10-05 | 1995-05-23 | Griffith Laboratories Worldwide, Inc. | Microencapsulation process |
DE4033419A1 (de) | 1990-10-20 | 1992-04-23 | Wolman Gmbh Dr | Polymere stickstoffverbindungen und metall fixierende saeuren enthaltende holzschutzmittel |
US5137892A (en) | 1990-12-12 | 1992-08-11 | Abbott Laboratories | Quinoline, naphthyridine and pyridobenzoxazine derivatives |
US5244653A (en) | 1991-05-01 | 1993-09-14 | Isp Chemicals Inc. | Glycine anhydride dimethylol as a biocide and preservative |
US5250236A (en) | 1991-08-05 | 1993-10-05 | Gasco Maria R | Method for producing solid lipid microspheres having a narrow size distribution |
ZA93929B (en) | 1992-02-18 | 1993-09-10 | Akzo Nv | A process for the preparation of biologically active materialcontaining polymeric microcapsules. |
US5352461A (en) | 1992-03-11 | 1994-10-04 | Pharmaceutical Discovery Corporation | Self assembling diketopiperazine drug delivery system |
US5310535A (en) | 1992-04-24 | 1994-05-10 | The Dow Chemical Company | Carboxamide modified polyamine chelators and radioactive complexes thereof for conjugation to antibodies |
US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
DE69434418T2 (de) * | 1993-04-22 | 2005-12-22 | Emisphere Technologies, Inc. | Orale Dareichungsform |
DE69413590D1 (de) | 1993-04-23 | 1998-11-05 | Rhone Poulenc Chimie | Polyanhydroasparaginsäure und seine bioabbaubaren Hydrolyseprodukte |
-
1994
- 1994-04-22 DE DE69434418T patent/DE69434418T2/de not_active Expired - Lifetime
- 1994-04-22 EP EP00118505A patent/EP1077070A3/en not_active Withdrawn
- 1994-04-22 AT AT94916578T patent/ATE204467T1/de not_active IP Right Cessation
- 1994-04-22 AT AT00103527T patent/ATE298561T1/de active
- 1994-04-22 CA CA2160693A patent/CA2160693C/en not_active Expired - Fee Related
- 1994-04-22 JP JP52359594A patent/JP4361601B2/ja not_active Expired - Lifetime
- 1994-04-22 AU AU68192/94A patent/AU6819294A/en not_active Abandoned
- 1994-04-22 WO PCT/US1994/004560 patent/WO1994023767A1/en active IP Right Grant
- 1994-04-22 ES ES94916578T patent/ES2163444T3/es not_active Expired - Lifetime
- 1994-04-22 EP EP94916578A patent/EP0696208B1/en not_active Expired - Lifetime
- 1994-04-22 IL IL10940394A patent/IL109403A0/xx unknown
- 1994-04-22 EP EP00103527A patent/EP1025840B1/en not_active Expired - Lifetime
- 1994-04-22 DE DE69428040T patent/DE69428040T2/de not_active Expired - Fee Related
- 1994-04-22 ES ES00103527T patent/ES2244367T3/es not_active Expired - Lifetime
- 1994-04-22 US US08/537,888 patent/US5766633A/en not_active Expired - Lifetime
-
2006
- 2006-07-12 JP JP2006192105A patent/JP4657164B2/ja not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005510535A (ja) * | 2001-11-29 | 2005-04-21 | エミスフィアー テクノロジーズ インコーポレイテッド | クロモリンナトリウムの経口投与用製剤 |
US8513300B2 (en) | 2001-11-29 | 2013-08-20 | Emisphere Technologies, Inc. | Formulations for oral administration of cromolyn sodium |
JP2007537301A (ja) * | 2004-05-14 | 2007-12-20 | エミスフェアー・テクノロジーズ・インク | 活性薬剤を送達するための化合物および組成物 |
Also Published As
Publication number | Publication date |
---|---|
EP0696208B1 (en) | 2001-08-22 |
CA2160693C (en) | 2010-03-16 |
ES2244367T3 (es) | 2005-12-16 |
JP4657164B2 (ja) | 2011-03-23 |
DE69434418T2 (de) | 2005-12-22 |
EP0696208A4 (en) | 1997-01-29 |
DE69434418D1 (de) | 2005-08-04 |
IL109403A0 (en) | 1994-07-31 |
DE69428040D1 (de) | 2001-09-27 |
WO1994023767A1 (en) | 1994-10-27 |
EP1077070A3 (en) | 2001-05-23 |
ES2163444T3 (es) | 2002-02-01 |
EP1025840A2 (en) | 2000-08-09 |
EP1077070A2 (en) | 2001-02-21 |
ATE204467T1 (de) | 2001-09-15 |
EP0696208A1 (en) | 1996-02-14 |
JP2006273875A (ja) | 2006-10-12 |
US5766633A (en) | 1998-06-16 |
CA2160693A1 (en) | 1994-10-27 |
AU6819294A (en) | 1994-11-08 |
JP4361601B2 (ja) | 2009-11-11 |
EP1025840B1 (en) | 2005-06-29 |
DE69428040T2 (de) | 2002-05-29 |
EP1025840A3 (en) | 2000-08-30 |
ATE298561T1 (de) | 2005-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08509474A (ja) | 経口薬剤移送組成物およびその方法 | |
US6461643B2 (en) | Oral drug delivery compositions and methods | |
US5811127A (en) | Desferrioxamine oral delivery system | |
US5451410A (en) | Modified amino acids for encapsulating active agents | |
CA2203033C (en) | Compounds and compositions for delivering active agents | |
US5447728A (en) | Desferrioxamine oral delivery system | |
US5976569A (en) | Diketopiperazine-based delivery systems | |
US5792451A (en) | Oral drug delivery compositions and methods | |
JP2003313157A (ja) | 活性剤デリバリー用化合物および組成物 | |
JPH09512279A (ja) | 薬剤移送用修飾アミノ酸 | |
JP2001524109A (ja) | 活性剤を輸送するための化合物および組成物 | |
JP2001513080A (ja) | 化合物及び活性剤を送達するための組成物 | |
WO1996009813A9 (en) | Diketopiperazine-based delivery systems | |
US20010003001A1 (en) | Compounds and compositions for delivering active agents | |
JPH08511545A (ja) | プロテイノイド担体並びにその製造方法および使用方法 | |
HU229049B1 (en) | Compound and compositions for delivering active ingredients | |
MXPA97002899A (en) | Compounds and compositions to supply acti agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040427 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040726 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040906 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041026 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060314 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060712 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20060831 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20071018 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080618 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080623 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080718 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080724 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090618 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090813 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120821 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120821 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130821 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |